Application of Nanoscaffolds and Mesenchymal Stem Cells in Tissue Engineering 2 2 Stem cell research has obtained much prominence in recent years for its therapeutic potential in dealing with serious diseases, many of which are essentially incurable by routine therapies. Mesenchymal stem cells with pluripotency and immunomodulatory properties are suitable candidates for tissue engineering and regenerative medicine. Today, nanofibrous scaffolds are widely used in tissue engineering to improve implantation, function, proliferation and infiltration of the cells. In this regard, porous and biodegradable scaffolds with microstructure and suitable physicalmechanical properties are prepared. We review the application of mesenchymal stem cells nanoscaffolds and in tissue engineering. Keywords: Mesenchymal stem cells, tissue engineering, tissue scaffolds 0 0 2013/01/22 1391/11/3 2015/01/3 1393/10/13 A Salimi A Salimi M Ghollasi M Ghollasi N Saki N Saki F Rahim F Rahim A Dehghanifard A Dehghanifard Sh Alizadeh Sh Alizadeh M Farshdousti Hagh M Farshdousti Hagh M Soleimani M Soleimani Mesenchymal stem cells, tissue engineering, tissue scaffolds ## ##

A Glance at the Cost of Chelation Therapy with Desferal and Exjade in Iran 2 2 Background: Thalassemia is a series of hemoglobinopathies in which the production of perfect hemoglobin is completely or partially suppressed. Using injectable iron chelators have been dominating treatment for the iron overload caused by recurrent blood transfusions in thalassemic patients, however, a new oral iron chelating drug (Exjade) have been recently introduced and might be cost effective compared to previous treatment methods. This study was undertaken to evaluate the cost of Exjade in comparison with injectable iron chelators. Patients and Methods: In this retrospective study, we calculated the cost of iron chelation with Deferoxamine mesylate or Desferal in three groups of patients including those with optimum moderate and poor compliance. Afterwards, we compared the cost with the cost of iron chelation using Exjade. The cost of drugs and treatment for complications caused by iron overload were both taken into account. Results: The average cost of treatment per year with Deferoxamine mesylate was 85601032 Rials for patients with poor compliance, 62739714 Rials for patients with moderate compliance, and 50118376 Rials for patients with optimum compliance. In addition, according to the latest price of Exjade in Iranian market, we found out a regular oral iron chelation therapy using Exjade, with a dose of 20 mg/kg, to cost 76650000 Rials per year. Conclusion: Our findings indicate that using Exjade is cost-effective for those patients who have poor compliance to parenteral treatment. More investigations should be implemented to find the social and economic impact of Exjade therapy on quality of life among patients needing iron chelation therapy. Keywords: Thalassemia, hemoglobinopathies, iron chelating agents, deferasirox, deferoxamine 1 5 2013/01/222013/01/22 1391/11/3 2015/01/32015/01/3 1393/10/13 M Hadipour Dehshal M Hadipour Dehshal M Karimi M Karimi MR Shah Ahmad Ghasemi MR Shah Ahmad Ghasemi Thalassemia, hemoglobinopathies, iron chelating agents, deferasirox, deferoxamine ## ##

Comparison of the Initial Treatment Results of N-myc Positive and N-myc Negative Neuroblastoma Patients 2 2 Background: Neuroblastoma is the most common extra cranial malignant solid tumor of childhood. Various molecular and cytogenetic factors have been implicated in the pathogenesis of neuroblastoma, some of which have proven useful in predicting clinical behavior. Over expression of the oncogen N-myc, is an important indicator of prognosis. Materials and Methods: Our study was performed from 2004 to 2008 in Mofid Children’s Hospital in Tehran, Iran. In our case control study patients who were diagnosed as neuroblastoma were enrolled. They were checked for N-myc by fluorescence in situ hybridization (FISH) method in tumor tissue. Initially all patients were treated with conventional chemotherapy then were accessed to define their responses. Results: In our study 18 patients were diagnosed as neuroblastoma. Twelve of them were female and six of them were male. They were 6 month to 6 years old. Eight patients were N-myc positive (case) and ten patients were N-myc negative (control). None of N-myc positive patients responded to conventional chemotherapy, but eight N-myc negative patients responded to conventional chemotherapy. N-myc in neuroblastoma had a significant correlation with the prognosis (PV =0.028). Conclusion: We suggest conventional chemotherapy for N-myc negative patients and intensive chemotherapy for N-myc positive patients to obtain the best results. Key words: Neuroblastoma, solid tumor, cancer, childhood, genetics 7 10 2013/01/222013/01/222013/01/22 1391/11/3 2015/01/32015/01/32015/01/3 1393/10/13 MT Arzania MT Arzania H Mahmoodi Nesheli H Mahmoodi Nesheli S Alavi S Alavi BS Shamsian BS Shamsian A Maasomnia Samakosh A Maasomnia Samakosh A Eghbali A Eghbali M Ahmadi M Ahmadi F Jadali F Jadali A Bijani A Bijani Neuroblastoma, solid tumor, cancer, childhood, genetics ## ##

Intravascular Hemolysis Due to Glucose‐6‐Phosphate Dehydrogenase Deficiency in a Patient with Aluminium Phosphide Poisoning 2 2 Aluminium Phosphide poisoning and glucose‐6‐phosphate dehydrogenase deficiency are two commonly seen clinical presentations in Iran. However, hemolysis associated with Aluminium Phosphide poisoning is very rare. We report a case of concurrent Aluminium Phosphide poisoning and glucose‐6‐phosphate dehydrogenase deficiency in a 24 year old man presenting with intravascular hemolysis. Key words: Glucosephosphate dehydrogenase deficiency, Aluminum Phosphide, hemolysis, poisoning 21 23 2013/01/222013/01/222013/01/222013/01/22 1391/11/3 2015/01/32015/01/32015/01/32015/01/3 1393/10/13 F Farnaghi F Farnaghi H Owliaey H Owliaey H Hassanian Moghadam H Hassanian Moghadam S Shadnia S Shadnia N Momtazmanesh N Momtazmanesh Glucosephosphate dehydrogenase deficiency, Aluminum Phosphide, hemolysis, poisoning ## ##